These modified cells target intracellular melanoma antigens presented on MHC molecules, and the platform is complemented by immune-mobilizing monoclonal TCRs against cancer (immTACs)—CD3-bispecific molecules such as tebentafusp (gp100-directed, already approved for MUM) and emerging PRAME-directed constructs—that recruit bystander T cells to the tumor. Here, PMEL is linked to melanoma.